Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

Viking Therapeutics ( VKTX -43.72%) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what ...

Viking's obesity pill VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in body ...

EDT Viking Therapeutics (VKTX) falls 29% to $29.60 after Phase 2 VK2735 test results Published first on TheFly – the ultimate source for ...

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...